VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO TAT 2022 | Current therapeutic landscape for small-cell lung cancer

Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the current therapeutic landscape for small-cell lung cancer (SCLC), including the epidemiology and mortality rates, likely causes, and current treatment options. First-line standard of care (SOC) is anti-PD-L1 immunotherapy combined with chemotherapy, with second-line SOC including topotecan. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter